D. E. Shaw & Co. Inc. Acquires New Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

D. E. Shaw & Co. Inc. bought a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 81,190 shares of the company's stock, valued at approximately $5,147,000. D. E. Shaw & Co. Inc. owned 0.27% of Disc Medicine at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in IRON. FMR LLC raised its stake in shares of Disc Medicine by 358.7% during the fourth quarter. FMR LLC now owns 1,866,248 shares of the company's stock valued at $118,320,000 after acquiring an additional 1,459,434 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Disc Medicine by 23.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company's stock valued at $88,421,000 after purchasing an additional 262,690 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Disc Medicine by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 1,068,246 shares of the company's stock worth $67,727,000 after buying an additional 18,716 shares during the period. Victory Capital Management Inc. grew its holdings in Disc Medicine by 7.4% during the 4th quarter. Victory Capital Management Inc. now owns 236,244 shares of the company's stock worth $14,978,000 after acquiring an additional 16,230 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Disc Medicine by 9.5% during the fourth quarter. Northern Trust Corp now owns 187,017 shares of the company's stock valued at $11,857,000 after buying an additional 16,299 shares during the period. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Stock Performance

Shares of NASDAQ IRON traded down $0.23 during trading on Thursday, reaching $48.67. The stock had a trading volume of 37,577 shares, compared to its average volume of 348,519. The company has a market cap of $1.69 billion, a P/E ratio of -12.22 and a beta of 0.77. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $68.73. The business's 50-day moving average price is $45.92 and its 200-day moving average price is $54.96.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mona Ashiya sold 5,738 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $54.11, for a total transaction of $310,483.18. Following the completion of the sale, the director now directly owns 186,541 shares of the company's stock, valued at $10,093,733.51. This trade represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William Jacob Savage sold 2,100 shares of the stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $50.17, for a total transaction of $105,357.00. Following the transaction, the insider now directly owns 66,398 shares of the company's stock, valued at $3,331,187.66. This represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 342,833 shares of company stock worth $18,602,418 in the last quarter. 4.24% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently commented on IRON. TD Cowen began coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They set a "buy" rating for the company. Morgan Stanley reiterated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. Stifel Nicolaus raised their target price on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, January 24th. BMO Capital Markets lifted their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a research note on Monday, May 12th. Finally, Scotiabank increased their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $98.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.